Expert insights:
Topics in HIV prevention

Back to Expert Insights

Identifying People Who May Need or Want PrEP Medication

Presented by: Alisha Clemons, NP on Wednesday, November 19, 2025 12:00 PM - 1:00 PM CT

Description: It is important to know what communities may have a higher likelihood of HIV acquisition, and identify people who want or need PrEP medication as one part of an overall HIV prevention strategy. See practical strategies to effectively initiate discussions about HIV prevention options and also get information on the critical role of PrEP medication for people who want or need it. We will also discuss DESCOVY FOR PrEP^® as an HIV prevention option.

These non-CME educational programs and speakers are sponsored by Gilead Sciences, Inc.

Please register to sign up for this event.

*Required field

xxx xxx xxxx

To learn more about how Gilead may use your information, please see our Global Privacy Statement.

I certify that I am a US healthcare professional.*

Text Reminder Opt-In

I consent to receive reminder communications from Gilead and its service providers to my mobile phone number provided, including text messages. Text and data rates may apply. I understand that I may opt out at any time by texting “STOP.”

Communication Consent

I agree and consent to receive emails and phone calls related to the administration of this webinar at the email address and phone number I have provided, including cell phone number if provided.*

I want to stay informed on related future webinars, events, and other informational materials by receiving communication via emails and text messages at the email address and phone number I have provided.

Errors with required field(s)

INDICATION & LIMITATION OF USE

DESCOVY^® for HIV-1 pre-exposure prophylaxis (PrEP) is indicated in at-risk adults and adolescents (≥35 kg) to reduce the risk of sexually acquired HIV-1 infection, excluding individuals at risk from receptive vaginal sex. HIV-1–negative status must be confirmed immediately prior to initiation.

Limitation of Use: DESCOVY FOR PrEP^® is not indicated in individuals at risk of HIV-1 from receptive vaginal sex because effectiveness in this population has not been evaluated.

INDICATION & LIMITATION OF USE

Limitation of Use: DESCOVY FOR PrEP^® is not indicated in individuals at risk of HIV-1 from receptive vaginal sex because effectiveness in this population has not been evaluated.

Expert insights:
Topics in HIV prevention

Identifying People Who May Need or Want PrEP Medication

Please register to sign up for this event.

INDICATION & LIMITATION OF USE

IMPORTANT SAFETY INFORMATION

BOXED WARNING: RISK OF DRUG RESISTANCE WITH USE OF DESCOVY FOR PrEP^® IN UNDIAGNOSED EARLY HIV‑1 INFECTION and POST-TREATMENT ACUTE EXACERBATION OF HEPATITIS B

Contraindication

Warnings and precautions

Adverse reactions

Drug interactions

Dosage and administration

INDICATION & LIMITATION OF USE

IMPORTANT SAFETY INFORMATION

BOXED WARNING: RISK OF DRUG RESISTANCE WITH USE OF DESCOVY FOR PrEP^® IN UNDIAGNOSED EARLY HIV‑1 INFECTION and POST-TREATMENT ACUTE EXACERBATION OF HEPATITIS B

Contraindication

Warnings and precautions

Adverse reactions

Drug interactions

Dosage and administration

DESCOVY® (emtricitabine/tenofovir alafenamide) HCP | Virtual Event Registration

Expert insights: Topics in HIV prevention

Identifying People Who May Need or Want PrEP Medication

Please register to sign up for this event.

INDICATION & LIMITATION OF USE

IMPORTANT SAFETY INFORMATION

BOXED WARNING: RISK OF DRUG RESISTANCE WITH USE OF DESCOVY FOR PrEP® IN UNDIAGNOSED EARLY HIV‑1 INFECTION and POST-TREATMENT ACUTE EXACERBATION OF HEPATITIS B

Contraindication

Warnings and precautions

Adverse reactions

Drug interactions

Dosage and administration

INDICATION & LIMITATION OF USE

IMPORTANT SAFETY INFORMATION

BOXED WARNING: RISK OF DRUG RESISTANCE WITH USE OF DESCOVY FOR PrEP® IN UNDIAGNOSED EARLY HIV‑1 INFECTION and POST-TREATMENT ACUTE EXACERBATION OF HEPATITIS B

Contraindication

Warnings and precautions

Adverse reactions

Drug interactions

Dosage and administration

This site is intended for US healthcare professionals

I am a healthcare professional

I am a patient or caregiver

Expert insights:
Topics in HIV prevention

BOXED WARNING: RISK OF DRUG RESISTANCE WITH USE OF DESCOVY FOR PrEP^® IN UNDIAGNOSED EARLY HIV‑1 INFECTION and POST-TREATMENT ACUTE EXACERBATION OF HEPATITIS B

BOXED WARNING: RISK OF DRUG RESISTANCE WITH USE OF DESCOVY FOR PrEP^® IN UNDIAGNOSED EARLY HIV‑1 INFECTION and POST-TREATMENT ACUTE EXACERBATION OF HEPATITIS B